Brief: Aridis Signs Exclusive Terms To Secure Worldwide Commercial Licenses For Pan-Ebola And Pan-Marburg Monoclonal Antibody Programs From Mapp Biopharmaceutical
05/12/2022 12:16
Dec 5 (Reuters) - Aridis Pharmaceuticals Inc ARDS.O :
* ARIDIS SIGNS EXCLUSIVE TERMS TO SECURE WORLDWIDE
COMMERCIAL
LICENSES FOR PAN-EBOLA AND PAN-MARBURG MONOCLONAL ANTIBODY
PROGRAMS FROM MAPP BIOPHARMACEUTICAL
* ARIDIS PHARMACEUTICALS - CO AND MAPPBIO HAVE COMMITTED TO
WORK
EXCLUSIVELY WITH EACH OTHER TO EXPEDITIOUSLY COMPLETE DEFINITIVE
LICENSING AGREEMENTS
Source text for Eikon: ID:nGNXY3zrn
Further company coverage: ARDS.O
Recent news on Aridis Pharmaceuticals
See all newsBrief: Aridis Pharmaceuticals Inc - On September 7 Nasdaq Announced That It Would Delist Common Stock Of Co
U.S. STOCKS ON THE MOVE-Pieris Pharma, Microsoft, Energy sector
U.S. STOCKS ON THE MOVE-Medtronic, Morgan Stanley, Bank of America
U.S. STOCKS ON THE MOVE-Teladoc Health, NVDIA, Chipotle
U.S. STOCKS ON THE MOVE-Pinterest, Sunrun, Tencent Music